Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There are many who feel that the achievement of a disease-modifying (DM) designation for a drug is an important goal in Alzheimer disease (AD) therapeutics. Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis. Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM. The available methods for establishing DM are fraught with logistical and analytic problems. Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail. Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.

Original languageEnglish (US)
Pages (from-to)147-149
Number of pages3
JournalAlzheimer's and Dementia
Volume2
Issue number3
DOIs
StatePublished - Jul 2006

Fingerprint

Alzheimer Disease
Pharmaceutical Preparations
Cerebrospinal Fluid
Biomarkers
Outcome Assessment (Health Care)
Clinical Trials
Therapeutics

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Drug therapy

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

@article{8432869de5524d478095aba385d8728e,
title = "Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying",
abstract = "There are many who feel that the achievement of a disease-modifying (DM) designation for a drug is an important goal in Alzheimer disease (AD) therapeutics. Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis. Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM. The available methods for establishing DM are fraught with logistical and analytic problems. Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail. Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.",
keywords = "Alzheimer's disease, Clinical trials, Drug therapy",
author = "Knopman, {David S}",
year = "2006",
month = "7",
doi = "10.1016/j.jalz.2006.03.010",
language = "English (US)",
volume = "2",
pages = "147--149",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying

AU - Knopman, David S

PY - 2006/7

Y1 - 2006/7

N2 - There are many who feel that the achievement of a disease-modifying (DM) designation for a drug is an important goal in Alzheimer disease (AD) therapeutics. Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis. Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM. The available methods for establishing DM are fraught with logistical and analytic problems. Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail. Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.

AB - There are many who feel that the achievement of a disease-modifying (DM) designation for a drug is an important goal in Alzheimer disease (AD) therapeutics. Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis. Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM. The available methods for establishing DM are fraught with logistical and analytic problems. Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail. Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.

KW - Alzheimer's disease

KW - Clinical trials

KW - Drug therapy

UR - http://www.scopus.com/inward/record.url?scp=33744929621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744929621&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2006.03.010

DO - 10.1016/j.jalz.2006.03.010

M3 - Article

C2 - 19595873

AN - SCOPUS:33744929621

VL - 2

SP - 147

EP - 149

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -